24 August 2010
Responding to the interim decision by NICE not to recommend bevacizumab (Avastin) as a treatment for metastic colorectal cancer, Mike Hobday, Head of Policy at Macmillan Cancer Support, said:
'We think this is devastating news for cancer patients with metastic colorectal cancer, especially as this drug could have a significant impact on peoples’ quality of life. Although a few extra weeks or months might not sound much to some people it can mean an awful lot to a family affected by cancer.
'Again this reiterates just how important it is that the government’s cancer drug fund comes into place sooner rather than later. On behalf of people living with cancer, Macmillan will hold the government to their £200 million commitment in order to ensure people with rarer cancers have fair access to clinically effective drugs.'
For more information and support call Macmillan free on 0808 808 00 00 or visit www.macmillan.org.uk/accesstotreatment.
For further information, please contact:
Julie Wills, Assistant Media & PR Officer, Macmillan Cancer Support
020 7840 4933
Note to editors:
About Macmillan Cancer Support
Macmillan Cancer Support improves the lives of people affected by cancer, providing practical, medical, emotional and financial support. Working alongside people affected by cancer, Macmillan works to improve cancer care. One in three of us will get cancer. Two million of us are living with it. If you are affected by cancer Macmillan can help.
Call the Macmillan Support Line on 0808 808 00 00, Monday to Friday, 9am to 8pm. Calls are free, including from mobiles, or visit www.macmillan.org.uk.